logo
Twitter
Discord
Email
logo
Enliven Therapeutics, Inc.

Enliven Therapeutics, Inc.

NASDAQ•ELVN
CEO: Mr. Samuel S. Kintz M.B.A.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2020-03-12
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.
Contact Information
6200 Lookout Road, Boulder, CO, 80301, United States
720-647-8519
www.enliventherapeutics.com
Market Cap
$1.31B
P/E (TTM)
-11.5
45.9
Dividend Yield
--
52W High
$26.48
52W Low
$13.30
52W Range
67%
3.2
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 3.2 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2024

Financial Dashboard

Q3 2025 Data

Revenue

$0.00+0.00%
4-Quarter Trend

EPS

-$0.32-33.33%
4-Quarter Trend

FCF

-$13.28M+8.70%
4-Quarter Trend

2025 Q2 Earnings Highlights

Key Highlights

Strong Cash Position Total cash and marketable securities reached $490.5M as of June 30, 2025, funding operations for at least 12 months.
Public Offering Proceeds Financing activities provided $218.6M net cash, primarily from the June 2025 Public Offering proceeds of $216.6M.
Asset Base Growth Total assets grew to $503.9M by June 30, 2025, driven by increased marketable securities holdings of $371.1M.
R&D Investment Increase Six-month R&D expenses rose to $46.4M, reflecting increased internal costs for salaries, benefits, and stock-based compensation.

Risk Factors

Continued Operating Losses Incurred net loss of $53.9M for six months ended June 30, 2025; expects operating losses to continue indefinitely.
ELVN-002 Strategic Shift Exploring strategic alternatives for ELVN-002; development will cease beyond 2025, impacting pipeline focus and future plans.
Regulatory Approval Uncertainty Success depends on clinical trials demonstrating safety/efficacy; failure to gain regulatory approval will substantially harm business.
Intellectual Property Defense Success relies on protecting IP; patent validity uncertain; litigation risk exists, potentially limiting competitive advantage.

Outlook

Prioritize ELVN-001 Advancement Prioritizing ELVN-001 advancement toward pivotal trial; exploring strategic alternatives for ELVN-002 program to manage resources.
Substantial Future Capital Requires substantial additional capital to fund development and commercialization infrastructure if product candidates are approved.
Increased Public Company Costs Expect general and administrative expenses to increase substantially due to ongoing compliance as a public company.
Growing R&D Expenses Expect R&D expenses to increase substantially over next several years advancing product candidates through clinical trials.

Peer Comparison

Revenue (TTM)

CureVac N.V.CVAC
$555.13M
+682.0%
Immatics N.V.IMTX
$141.50M
+83.2%
Wave Life Sciences Ltd.WVE
$109.23M
+103.7%

Gross Margin (Latest Quarter)

Immatics N.V.IMTX
100.0%
+0.5 pp
Dianthus Therapeutics, Inc.DNTH
75.0%
-25.0 pp
Nuvation Bio Inc.NUVB
74.5%
+182.9 pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
NUVB$1.66B-7.7-55.0%1.7%
DNTH$1.48B-12.2-33.0%0.2%
SYRE$1.42B-54.6-31.2%0.0%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Reports
All Years

  • Form 10-Q - Q3 2025

    Period End: Sep 30, 2025|Filed: Nov 12, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.32-33.3%
    N/A

  • Form 10-Q - Q2 2025

    Period End: Jun 30, 2025|Filed: Aug 13, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.49+19.5%
    N/A

  • Form 10-Q - Q1 2025

    Period End: Mar 31, 2025|Filed: May 14, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.57+5.6%
    N/A

  • Form 10-K - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 13, 2025|
    Revenue: $0.00+0.0%
    |
    EPS: $-1.89+6.0%
    N/A

  • Form 10-Q - Q3 2024

    Period End: Sep 30, 2024|Filed: Nov 13, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.48-5.9%
    N/A

  • Form 10-Q - Q2 2024

    Period End: Jun 30, 2024|Filed: Aug 13, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.41+0.0%
    N/A

  • Form 10-Q - Q1 2024

    Period End: Mar 31, 2024|Filed: May 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-0.54-32.5%
    N/A

  • Form 10-K - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 14, 2024|
    Revenue: $0.00+0.0%
    |
    EPS: $-2.01+66.7%
    N/A